Jørgen Søberg Petersen, MD, PhD, DMSc, MBA, is Senior Partner at Novo Holdings and previously served as the Hemab Board Chair. Dr. Pedersen trained in medicine in Denmark and in the United States. During his 20 years in the pharmaceutical industry, he served in executive R&D roles at Lundbeck, Zealand Pharma, Merck, and Novo Nordisk. He co-founded Zealand Pharma and built the company to exit. He has extensive experience in rare disease development and financing of rare disease companies. He earned an MD, PhD in Pharmacology, and DMSc from the University of Copenhagen, Denmark, and an MBA from the Technical University of Denmark.